S

Sanofi

Global pharma company; vaccines and R&D

Transversal Finance Lead

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
$147.9k - $205k+ Target bonus
Expert
Bachelor's, MBA
Toronto, ON, Canada
HybridHybrid working model; up to 10% business travel may be required.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A university degree in Accounting, Finance, Business Administration, or a related field is required.
  • A minimum of 10 years of progressive finance experience is required, including experience in FP&A, Corporate Finance, Finance Business Partnering, and/or Finance Operations.
  • Demonstrated experience leading finance transformation or digital/AI initiatives in a complex, multi-GBU or multinational environment.
  • Prior experience managing or collaborating with offshore/nearshore finance hubs, such as shared service centers or centers of excellence.
  • A proven track record of delivering through significant organizational change without direct authority.
  • A visionary digital mindset, with a genuine passion for AI, automation, and data-driven finance and the ability to translate technology potential into practical business value.
  • The ability to influence, align, and mobilize stakeholders across GBUs, corporate functions, and global teams without direct authority.
  • Advanced financial acumen and deep expertise in P&L management, forecasting, budgeting, and financial modelling.
  • The ability to synthesize complex financial data into clear narratives for senior executives.
  • High learning agility and comfort with ambiguity in a fast-changing environment.
  • Strong project management skills and the ability to manage multiple high-priority workstreams simultaneously.
  • A collaborative and inclusive leadership style that builds trust and fosters continuous improvement.
  • A results-oriented strategic mindset that balances short-term delivery with long-term capability building.
  • Strong leadership and strategic thinking across all areas of responsibility.
Responsibilities
  • Serve as the single transversal finance lead for Canada, ensuring a unified One-Canada financial view across Specialty Care, General Medicines, and Vaccines.
  • Coordinate legal entity oversight for all Canadian Sanofi entities, including statutory reporting, tax compliance coordination, and regulatory financial submissions.
  • Lead corporate functions partnership as the primary finance interface, aligning financial planning with Sanofi priorities.
  • Coordinate consolidated Canada-wide financial reporting, including monthly actuals, rolling forecasts, the Strategic Plan, and the Budget.
  • Act as CFO Canada deputy for transversal financial matters and prepare and present consolidated Canada financials and analytics to senior leadership, including Country Council.
  • Drive internal control excellence across transversal finance processes, ensuring zero material deficiencies and full audit readiness.
  • Lead and arbitrate cross-functional financial governance, resolving conflicts and aligning priorities across GBUs and corporate functions.
  • Champion the One Finance culture across Canada by standardizing processes, tools, and ways of working.
  • Own the digital and AI transformation agenda for Finance Canada as the primary champion and delivery lead for technology-enabled finance capabilities.
  • Lead the design, deployment, and continuous improvement of AI-based P&L forecasting models for Canada in partnership with Global Digital and Data Science teams.
  • Partner with Commercial, Supply Chain, and Medical functions to extend digital and AI capabilities beyond Finance and embed data-driven decision-making across the affiliate.
  • Represent Canada Finance on global digital finance initiatives and ensure local needs are reflected in global tool design and rollout.
  • Drive adoption of advanced analytics, automation, and self-service reporting tools, including Power BI and AI-driven scenario planning, across the finance community.
  • Identify and pilot emerging AI use cases relevant to the Canadian market, such as GTN optimization, demand forecasting, and working capital analytics.
  • Build digital fluency within the Finance team through training, upskilling, and change management.
  • Act as a thought leader and internal consultant on AI and digital finance topics for the broader Canada leadership team.
  • Serve as the primary Canada finance liaison to the Bogotá Hub, ensuring effective collaboration, clear governance, and high-quality delivery of hub-supported finance activities.
  • Lead the transition of Gross-to-Net processes to the Bogotá Hub, including scoping, knowledge transfer, process documentation, quality assurance, and stabilization.
  • Define and monitor service-level expectations with the Hub and establish KPIs and regular review cadences to ensure delivery quality and continuous improvement.
  • Partner with Hub leadership and Global Finance Operations to expand the scope of Hub-supported activities, identifying further opportunities for transversal finance tasks.
  • Ensure robust change management and communication for Hub transition activities while maintaining team engagement and business continuity.
  • Act as an escalation point for Hub-related issues that affect Canada finance operations.
  • Provide analytical and strategic support to the CFO Canada, including executive-level financial presentations, ad hoc analyses, and scenario modelling.
  • Partner with GBU Finance Business Partners to ensure consistency of financial frameworks, assumptions, and reporting standards.
  • Support GBU Finance Business Partners in preparing and challenging Budget, Rolling Forecast, and Strategic Plan submissions, applying a transversal lens and identifying cross-GBU synergies or risks.
  • Lead or co-lead Canada-wide financial projects requiring cross-GBU coordination, such as Healthy Savings, T&E cost optimization initiatives, and M&A/BD support.
  • Provide financial modelling and business case support for strategic investments, partnerships, and operational decisions.
  • Represent Finance Canada in North America and Global finance forums as delegated by the CFO Canada.
  • Coordinate with the CFO Canada, GBU General Managers, GBU Finance Business Partners, North America CFO, Bogotá Hub Finance Leadership, Global Digital and Data Science teams, Corporate Finance, Legal Entity Controllers, Internal Control and External Auditors, corporate functions, M&S and R&D Finance, Tax, and Treasury.
  • Travel for business as required, up to 10%.
Desired Qualifications
  • An MBA, CPA, CFA, or equivalent advanced qualification is preferred.
  • Formal training or certification in data analytics, AI/ML applications in finance, or digital transformation is an asset.
  • Experience in the pharmaceutical, life sciences, or consumer health industry is preferred.
  • Familiarity with GTN processes, legal entity management, and statutory reporting in Canada is a strong asset.
  • Bilingual English/French ability is an asset given the Canadian market context.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...